Our Science

We are building a product pipeline for rapid control of existing and emerging infectious diseases.

​

Ongoing studies for additional TPOXX indications

 

Post-exposure prophylaxis

 

Post-exposure prophylaxis (PEP) holds immense potential medical benefit, particularly within immunocompromised patient populations. It offers a crucial line of defense against infectious diseases following potential exposure and prior to display of symptoms, thereby safeguarding vulnerable individuals from severe complications. TPOXX is currently being evaluated for PEP treatment in adults exposed to smallpox. This program is funded and supported in collaboration with the U.S. Department of Defense.

​

Liquid suspension pediatric formulation

​

A smallpox outbreak affecting children needs a therapy to reduce severe illness and death. An oral liquid suspension pediatric formulation of TPOXX is currently being investigated for the treatment of smallpox in patients weighing less than 13 kg. This program is funded and supported in collaboration with Biomedical Advanced Research and Development Authority (BARDA).